AU1615701A - Compositions and methods for regulating tumor-associated antigen expression - Google Patents

Compositions and methods for regulating tumor-associated antigen expression

Info

Publication number
AU1615701A
AU1615701A AU16157/01A AU1615701A AU1615701A AU 1615701 A AU1615701 A AU 1615701A AU 16157/01 A AU16157/01 A AU 16157/01A AU 1615701 A AU1615701 A AU 1615701A AU 1615701 A AU1615701 A AU 1615701A
Authority
AU
Australia
Prior art keywords
compositions
methods
associated antigen
antigen expression
regulating tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
AU16157/01A
Inventor
James T. Kurnick
Peter J. Van Den Elsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universiteit Leiden
General Hospital Corp
Original Assignee
Universiteit Leiden
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universiteit Leiden, General Hospital Corp filed Critical Universiteit Leiden
Publication of AU1615701A publication Critical patent/AU1615701A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A61K39/464491—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
AU16157/01A 1999-11-16 2000-11-15 Compositions and methods for regulating tumor-associated antigen expression Withdrawn AU1615701A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16580699P 1999-11-16 1999-11-16
US60165806 1999-11-16
PCT/US2000/031508 WO2001035903A2 (en) 1999-11-16 2000-11-15 Compositions and methods for regulating tumor-associated antigen expression

Publications (1)

Publication Number Publication Date
AU1615701A true AU1615701A (en) 2001-05-30

Family

ID=22600560

Family Applications (3)

Application Number Title Priority Date Filing Date
AU22362/01A Abandoned AU2236201A (en) 1999-11-16 2000-11-15 Compositions and methods for regulating tumor-associated antigen expression
AU20432/01A Abandoned AU2043201A (en) 1999-11-16 2000-11-15 Compositions and methods for regulating tumor-associated antigen expression
AU16157/01A Withdrawn AU1615701A (en) 1999-11-16 2000-11-15 Compositions and methods for regulating tumor-associated antigen expression

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AU22362/01A Abandoned AU2236201A (en) 1999-11-16 2000-11-15 Compositions and methods for regulating tumor-associated antigen expression
AU20432/01A Abandoned AU2043201A (en) 1999-11-16 2000-11-15 Compositions and methods for regulating tumor-associated antigen expression

Country Status (5)

Country Link
EP (1) EP1232178A2 (en)
JP (1) JP2003515535A (en)
AU (3) AU2236201A (en)
CA (1) CA2388517A1 (en)
WO (3) WO2001036461A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1388734B1 (en) * 2002-08-01 2004-03-03 MTM Laboratories AG Method for solution based diagnosis
ATE476652T1 (en) * 2005-06-23 2010-08-15 Siemens Healthcare Diagnostics QUANTITATIVE ASSAY FOR RAS P21 IN BODY FLUID
JP5397692B2 (en) * 2007-11-28 2014-01-22 国立大学法人名古屋大学 Malignant melanoma antigen expression increasing agent and use thereof
JP5739816B2 (en) 2008-12-19 2015-06-24 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ TFPI inhibitors and methods of use
NZ603028A (en) 2010-03-19 2014-11-28 Baxter Healthcare Sa Tfpi inhibitors and methods of use
KR102263685B1 (en) 2012-03-21 2021-06-11 다케다 야쿠힌 고교 가부시키가이샤 Tfpi inhibitors and methods of use
JP6464140B2 (en) 2013-03-13 2019-02-06 ヘルス リサーチ インコーポレイテッドＨｅａｌｔｈ Ｒｅｓｅａｒｃｈ， Ｉｎｃ． Compositions and methods for using recombinant T cell receptors to directly recognize tumor antigens
US9550828B2 (en) * 2013-09-05 2017-01-24 Boise State University Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders
US11633457B2 (en) 2019-04-11 2023-04-25 Boise State University Pharmaceutical compositions comprising oncostatin m (OSM) antagonist derivatives and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618715A (en) * 1985-12-20 1997-04-08 Oncogen Limited Partnership Oncostatin M and novel compositions having anti-neoplastic activity
NZ237533A (en) * 1990-03-29 1992-12-23 Bristol Myers Squibb Co Monoclonal antibodies which bind to oncostatin m, cell lines producing them
IL97622A (en) * 1990-03-29 1997-06-10 Oncogen Limited Partnership Se Monoclonal antibodies that inhibit growth of kaposi's sarcoma
US6020478A (en) * 1997-02-28 2000-02-01 Incyte Pharmaceuticals, Inc. Human tumor-associated antigen

Also Published As

Publication number Publication date
AU2043201A (en) 2001-05-30
WO2001036472A3 (en) 2002-01-10
WO2001035903A2 (en) 2001-05-25
WO2001036461A3 (en) 2002-01-17
AU2236201A (en) 2001-05-30
WO2001036461A2 (en) 2001-05-25
WO2001036472A2 (en) 2001-05-25
EP1232178A2 (en) 2002-08-21
CA2388517A1 (en) 2001-05-25
JP2003515535A (en) 2003-05-07

Similar Documents

Publication Publication Date Title
AU3933200A (en) Compositions and methods for controlling pests
AUPQ419099A0 (en) Novel compositions and methods
AU2001239947A1 (en) Methods and compositions for regulating adipocytes
AU4133701A (en) Methods and compositions for peptide synthesis
AU2002354929A1 (en) Antibodies specific for nanotubes and related methods and compositions
AU7859900A (en) Compositions and methods for wt1 specific immunotherapy
AU2001293189A1 (en) Compositions and methods for regulating apoptosis
AU2002364708A1 (en) Novel compositions and methods for cancer
AU1940301A (en) Tick antigens and compositions and methods comprising them
AU2236201A (en) Compositions and methods for regulating tumor-associated antigen expression
AU2977500A (en) Advanced antigen presentation platform
AU2001275409A1 (en) Methods and compositions for controlled polypeptide synthesis
AU7474100A (en) Methods and compositions for reducing immune response
AU6278300A (en) Tumor-associated antigen (r11)
AU2001243635A1 (en) Methods and compositions for regulating memory consolidation
AU2002218919A1 (en) Compositions and methods for regulating receptor clustering
AU3283500A (en) Tumor-associated antigen
AU6094200A (en) Nor gene compositions and methods for use thereof
AU2002337943A1 (en) Novel compositions and methods for cancer
AU1597001A (en) Compositions and methods for modifying an immune response against tropomyosin
AU7572198A (en) Tumor-associated antigen
AU2001251242A1 (en) Methods and compositions for regulating memory consolidation
AU5243899A (en) Methods and compositions for using moclobemide
AUPO982097A0 (en) Methods and compositions for use therein
AU8513698A (en) Methods and compositions for designing vaccines

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase